EUCTR2006-006436-22-ITActive, not recruitingNot Applicable
A multicenter Study Evaluating the Efficacy of Nifedipine GITS ? Telmisartan Combination in Blood Pressure Control and Beyond: comparison of two strategies. - TALENT
Conditions
Drugs
Trial Snapshot
- Phase
- Not Applicable
- Status
- Active, not recruiting
- Sponsor
- BAYER
- Enrollment
- 400
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional clinical trial of medicinal product
Eligibility Criteria
- Sex
- All
Inclusion Criteria
- •- Hypertension (office systolic blood pressure > 135 mmHg), untreated or poorly controlled but stable antihypertensive regimen for >= 4 weeks - Presence of type 2 diabetes mellitus or target organ damage (echocardiographic or electrocardiographic left ventricular hypertrophy or microalbuminuria ) - Presence of a metabolic syndrome, i.e at least two of the following: (a) impaired glucose tolerance (fasting plasma glucose 110 ? 125 mg/dl) (b) raised serum triglycerides (>= 150 mg/dl) (c) low HDL cholesterol (males: < 40 mg/dl, females: < 50 mg/dl) (d) waist circumference >102 cm in men and >88 cm in women - Age: 18-75 years - Negative pregnancy test in females - Written informed consent
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
Exclusion Criteria
- •- Ongoing treatment with the following drugs: ACE-inhibitors (e.g. captopril, benazepril, enalapril, lisinopril, fosinopril, ramipril, perindopril, quinapril, moexipril, and trandolapril), AT1-antagonists (e.g. losartan, candesartan, eprosartan, telmisartan) or calcium-antagonists (e.g. amlodipine, felodipine, isradipine, nifedipine, nimodipine) that cannot be withdrawn. - Concomitant treatment with other antihypertensive medication that cannot be safely withdrawn at entry. - Concomitant treatment with known cytochrome P450-3A4 inhibitors (e.g cimetidine, anti-HIV protease inhibitors e.g. ritonavir, azole anti-mycotics eg. Ketoconazole, digoxin, quinidine, tacrolimus) or inducers such as anti-epileptic drugs (eg. phenytoin, carbamazepine and phenobarbitone) or rifampicin - Concomitant treatment with potassium sparing diuretics. - Malignant, severe or labile essential hypertension, orthostatic hypotension - Cardiovascular shock - Evidence of secondary form of hypertension, including coarctation of the aorta, hyperaldosteronism, renal artery stenosis or pheochromocytoma - Myocardial infarction or unstable angina within the previous 12 months - Severe cardiac valve disease - Severe rhythm or conduction disorder: - bradycardia on physical examination at rest (HR < 50/min) - tachycardia on physical examination at rest (HR > 100/min) - frequent complex ventricular arrythmias - atrial fibrillation - intraventricular conduction disorders, Wolf Parkinson White syndrome - sino-atrial, second degree or third degree A-V block - baseline QTc > 450 msec - Cerebrovascular ischaemic event (stroke, transient ischaemic attack) within the previous 12 months - History of intra-cerebral haemorrhage or sub-arachnoid haemorrhage within the previous 12 months - Type 1 diabetes mellitus - Proteinuria (determined by uristix) - BMI > 34 - Uncorrected hypokalemia or hyperkalemia, potassium outside the range 3.0 to 5.5 mmol/l - Sodium depletion and/or hypovolemia - Gastrointestinal disease resulting in the potential for malabsorption. - Severe gastrointestinal tract narrowing - Kock pouch (ileostomy after proctocolectomy) - Cholestasis or biliary obstruction - Liver disease or transaminase (AST, ALT) levels > 3 x the upper limit of normal range. - Renal failure, creatinine >2.0 mg/dl - Any malignant disease that has required treatment within the last five years. - Dementia or psychosis. - History of non-compliance, alcoholism or drug abuse. - Treatment with any other investigational drug in the 30 days prior to entering the study. - Pregnancy and lactation - Known state of allergy, hypersensitivity to nifedipine or any other dihydropyridine or to telmisartan - Any surgical or medical condition which, at the discretion of the investigator, place the subject at higher risk from his/her participation in the study or are likely to prevent the subject from complying with the requirements of the study or completing the trial period. - History of non compliance to medical regimens or subjects unwilling to comply with the study protocol.
Investigators
Similar Trials
Recruiting
Not Applicable
Multicenter retrospective study of efficacy of the combination of cetuximab and paclitaxel in patients with recurrent and/or metastatic oral squamous cell carcinomaRecurrent and/or metastatic oral squamous cell carcinomaJPRN-UMIN000029351agasaki university50
Recruiting
Not Applicable
A multicenter prospective study of the efficacy of prophylactic clip closure for prevention of delayed bleeding after colorectal ESD (endoscopic submucosal dissection)Colorectal neoplasmsJPRN-UMIN000036734Osaka University Graduate School of Medicine45
Recruiting
Not Applicable
A prospective multicenter study of the efficacy of pranlukast hydrate for infant patients with acute wheezing illness caused by RS virus infectioRepsratory Syncytial virus: RSVJPRN-UMIN000025608agoya University Hospital160
Completed
Phase 3
Study to evaluate the effect of two herbal drugs NIFAy.C-19(CONTAZAP)and AYUSH 64 in corona patients.CTRI/2021/01/030169ational Innovation FoundationIndia120
Not yet recruiting
Not Applicable
Multidomain Intervention Via a None-face-to-face Platform in Mild Cognitive ImpairmentMental and behavioural disordersKCT0007184Inha University Hospital100